Clinical Wins and Legal Strains Might Change The Case For Investing In Boston Scientific (BSX)

• In late March 2026, Boston Scientific reported a series of medical device milestones, including FDA 510(k) clearance for its Asurys Fluid Management System and strong clinical trial results for its WATCHMAN FLX and EKOS systems across urology, atrial fibrillation and pulmonary embolism care.
• At the same time, the company has been hit by multiple securities class action lawsuits over allegedly misleading statements about its U.S. Electrophysiology segment, creating a contrast between clinical progress and rising legal and guidance-related uncertainty.
• We’ll now examine how the clash between positive WATCHMAN FLX trial data and mounting electrophysiology lawsuits may reshape Boston Scientific’s investment narrative.

Find 62 companies with promising cash flow potential yet trading below their fair value.

Boston Scientific Investment Narrative Recap

To own Boston Scientific today, you need to believe its diversified, innovation-led device portfolio can offset short term turbulence in electrophysiology. The most important near term catalyst is the April 22 earnings update, where the market will look for clarity on WATCHMAN adoption versus softer EP trends. The biggest current risk is the cluster of EP-related securities lawsuits and guidance uncertainty, which could weigh on valuation until management provides more detailed visibility.

The CHAMPION AF results for WATCHMAN FLX are the clearest link between the recent news and that earnings catalyst. Showing non inferior stroke prevention versus NOACs with meaningfully lower bleeding reinforces WATCHMAN as a cornerstone therapy in atrial fibrillation care. For shareholders, the key question is whether this clinical win begins to show up in higher WATCHMAN procedure volumes soon enough to meaningfully offset pressures in U.S. electrophysiology and justify the premium multiple.

Yet in contrast to the strong WATCHMAN data, the unresolved EP lawsuits and allegations of misleading growth commentary are information investors should be aware of before they...

Read the full narrative on Boston Scientific (it's free!)

Boston Scientific's narrative projects $26.9 billion revenue and $5.1 billion earnings by 2029. This requires 10.3% yearly revenue growth and about a $2.2 billion earnings increase from $2.9 billion today.

Uncover how Boston Scientific's forecasts yield a $100.31 fair value, a 64% upside to its current price.

Exploring Other Perspectives

While the consensus view already leans positive, the most optimistic analysts were assuming revenue near US$28.0 billion and earnings around US$6.0 billion by 2029, which makes the recent WATCHMAN and EKOS data especially important if you are weighing that faster growth story against the more cautious concerns around electrophysiology and legal risk.

Explore 5 other fair value estimates on Boston Scientific - why the stock might be worth just $98.72!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Boston Scientific research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Boston Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Boston Scientific's overall financial health at a glance.

Seeking Other Investments?

Our top stock finds are flying under the radar-for now. Get in early:

• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com